The FDA-approved weight loss drug — complete patient guide.
Wegovy (semaglutide 2.4 mg) is a once-weekly injectable medication FDA-approved specifically for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related health condition. It is manufactured by Novo Nordisk — the same company that makes Ozempic.
Wegovy was approved by the FDA in June 2021 and represented a major milestone — the first drug approved for chronic obesity management since Qsymia in 2012. The SELECT trial (2023) further demonstrated that Wegovy reduces the risk of major cardiovascular events (heart attacks, strokes) by 20% in people with established cardiovascular disease — making it the only weight loss drug with a proven heart benefit.
Activates GLP-1 receptors in the hypothalamus, significantly reducing hunger signals. Patients report feeling "full faster" and losing interest in food — not just eating less, but genuinely wanting less.
Delays gastric emptying, extending satiety after meals. Food moves through your stomach more slowly, keeping you fuller longer. This is also why nausea is a common side effect, especially early on.
The SELECT trial showed 20% reduction in major cardiovascular events. Beyond weight loss, semaglutide appears to have direct protective effects on the cardiovascular system — making it uniquely valuable for high-risk patients.
Wegovy has a 5-step dose escalation lasting 16 weeks before reaching the 2.4mg maintenance dose. This gradual approach is critical for minimizing nausea and GI side effects. Do not rush it.
Side effects are similar to Ozempic but may be more pronounced at the higher 2.4mg maintenance dose. GI symptoms are the most common and typically improve after the first 2–3 months.
| Scenario | Monthly Cost |
|---|---|
| List price | ~$1,349 |
| Commercial insurance (if covered) | Varies widely ($0–$500+) |
| Novo Nordisk savings card (commercially insured, eligible) | ~$0–$199/mo |
| Medicare Part D (new 2026 coverage) | ~$150–$300/mo (est.) |
| No insurance, no savings card | ~$1,349 |
| Patient Assistance Program | $0 if income-eligible |
Same drug (semaglutide), different doses and approvals. See the Ozempic page for full details. Key summary:
The landmark SURMOUNT-5 trial (published 2025) directly compared Wegovy vs Zepbound. The results clearly favored tirzepatide (Zepbound).
| Factor | Wegovy | Zepbound |
|---|---|---|
| Active Ingredient | Semaglutide | Tirzepatide |
| Mechanism | GLP-1 agonist | GLP-1 + GIP dual agonist |
| Avg Weight Loss (SURMOUNT-5) | ~13–15% | ~20% (47% more) |
| Heart Disease Proof | ✅ Proven (SELECT trial) | ⏳ Trial ongoing |
| List Price | ~$1,349/mo | ~$1,059/mo |
Bottom line: Zepbound produces more weight loss at a lower list price. Wegovy has the advantage of proven cardiovascular benefit data. If you have heart disease, Wegovy's proven benefit matters. If maximum weight loss is the goal and heart disease isn't a factor, Zepbound or Mounjaro may be the better choice.
Clinical trials showed an average weight loss of ~15% of body weight at 68 weeks. However, there is wide individual variation. About one-third of patients lose more than 20%, while some lose less than 5%. Results depend on diet, exercise, dose reached, genetics, and how long you stay on the medication.
Most patients notice reduced appetite within 2–4 weeks. Visible weight loss typically starts around weeks 4–8. The most significant weight loss occurs between months 4–12 as the dose is maximized and the body adapts. Maximum benefit is typically seen at week 68 in clinical trials.
Coverage has improved significantly in 2025–2026. Medicare Part D now covers Wegovy for patients with obesity. Commercial insurance coverage varies — many large employers now cover it, while others still don't. Medicaid coverage varies by state. Always call your insurance to verify prior authorization requirements.
Yes — Wegovy is approved for patients with type 2 diabetes who also have obesity. However, if your doctor prescribes it primarily for diabetes management, insurance may prefer Ozempic (cheaper, diabetes-specific approval). Discuss with your prescriber and insurance company.
"Wegovy face" (and more broadly, "Ozempic face") is a colloquial term for facial volume loss that can occur with rapid weight loss on GLP-1 medications. As you lose body fat quickly, the face can appear gaunt or aged. This is a cosmetic concern, not a medical one. Slower weight loss, adequate nutrition, and resistance training can help minimize it.